Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole

ESR1 mutations are frequently acquired in hormone-resistant metastatic breast cancer (MBC). CDK4/6 inhibition along with endocrine therapy is a promising strategy in hormone receptor-positive MBC. However, the incidence and impact of ESR1 mutations on clinical outcome in patients treated with CDK4/6...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyanchandani, Rekha, Kota, Karthik J., Jonnalagadda, Amruth R., Minteer, Tanya, Knapick, Beth A., Oesterreich, Steffi, Brufsky, Adam M., Lee, Adrian V., Puhalla, Shannon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620144/
https://www.ncbi.nlm.nih.gov/pubmed/28978004
http://dx.doi.org/10.18632/oncotarget.11383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620144/
https://www.ncbi.nlm.nih.gov/pubmed/28978004
http://dx.doi.org/10.18632/oncotarget.11383

Ejemplares similares